TY - JOUR
T1 - H-ras mutation is an additional event of sarcomatous transformation in aerodigestive spindle cell carcinoma
AU - Shiratsuchi, Hideki
AU - Hirakawa, Naoya
AU - Saito, Tsuyoshi
AU - Oda, Yoshinao
AU - Yamamoto, Hidetaka
AU - Tomita, Kichinobu
AU - Yamamoto, Tomoya
AU - Tsuneyoshi, Masazumi
PY - 2004/3
Y1 - 2004/3
N2 - The conversion from a carcinomatous component to a sarcomatous one in spindle cell carcinoma (SPCC) of the upper aerodigestive tract is thought to occur via a series of molecular alterations; however the detailed mechanism is still unknown. We examined mutations at the H-ras and p53 genes in 16 SPCCs of upper aerodigestive tracts using PCR-RFLP, PCR-SSCP and direct sequencing analysis. The two distinct components, sarcomatous and carcinomatous components in SPCC, were analyzed independently. p53 mutations were detected in both components of SPCC (50.0%, 8/16), and those in the sarcomatous component were completely in accordance with those in the carcinomatous one. In contrast, H-ras mutations were detected only in the sarcomatous component (12.5%, 2/16), and not in the carcinomatous one (0%, 0/16). There was a statistically significant difference in prognosis between the patients with the H-ras mutation (n=2) and those without (n=14); the former had poorer prognosis (P=0.0049). Our results seem to suggest that the H-ras mutation is a relatively uncommon event in SPCC; however, the presence of H-ras mutations may be associated with a more malignant potential in SPCC, while actually occurring during the sarcomatous change itself.
AB - The conversion from a carcinomatous component to a sarcomatous one in spindle cell carcinoma (SPCC) of the upper aerodigestive tract is thought to occur via a series of molecular alterations; however the detailed mechanism is still unknown. We examined mutations at the H-ras and p53 genes in 16 SPCCs of upper aerodigestive tracts using PCR-RFLP, PCR-SSCP and direct sequencing analysis. The two distinct components, sarcomatous and carcinomatous components in SPCC, were analyzed independently. p53 mutations were detected in both components of SPCC (50.0%, 8/16), and those in the sarcomatous component were completely in accordance with those in the carcinomatous one. In contrast, H-ras mutations were detected only in the sarcomatous component (12.5%, 2/16), and not in the carcinomatous one (0%, 0/16). There was a statistically significant difference in prognosis between the patients with the H-ras mutation (n=2) and those without (n=14); the former had poorer prognosis (P=0.0049). Our results seem to suggest that the H-ras mutation is a relatively uncommon event in SPCC; however, the presence of H-ras mutations may be associated with a more malignant potential in SPCC, while actually occurring during the sarcomatous change itself.
UR - http://www.scopus.com/inward/record.url?scp=4644275125&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=4644275125&partnerID=8YFLogxK
U2 - 10.3892/or.11.3.597
DO - 10.3892/or.11.3.597
M3 - Article
C2 - 14767509
AN - SCOPUS:4644275125
SN - 1021-335X
VL - 11
SP - 597
EP - 604
JO - Oncology Reports
JF - Oncology Reports
IS - 3
ER -